Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 145

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 145
---
 of 100 percent of the outstanding equity of Relievant Medsystems, Inc. (Relievant), a privately held medical technology company that developed and commercialized the Intracept® Intraosseous 

81

Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction consisted of an upfront cash payment of $794 million, net of cash acquired, and additional sales-based milestones over the three years following the transaction close. These milestones, certain of which are uncapped, were estimated to have a fair value of $273 million as of the acquisition date. The Relievant business is being integrated into our Neuromodulation division. Purchase Price Allocation We accounted for these transactions as business combinations in accordance with FASB ASC Topic 805. The final purchase prices were comprised of the amounts presented below: (in millions)Acotec(1)ApolloRelievantPayment for acquisition, net of cash acquired (2)$381 $636 $794 Fair value of contingent consideration— — 273 $381 $636 $1,067 (1) Excludes approximately $140 million of cash on hand at the closing of the transaction(2) Related to Acotec, represents our majority stake investmentWe recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing date of the transaction. The final purchase price allocations were comprised of the components presented below, with the excess of the purchase price over the fair value of net identifiable assets acquired recorded to goodwill:(in millions)AcotecApolloRelievantGoodwill$337 $378 $731 Amortizable intangible assets334 248 325 Other assets acquired93 50 24 Liabilities assumed(48)(33)(15)Net deferred tax liabilities(76)(5)1 Fair value of noncontrolling interest(259)— — $381 $636 $1,067 The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and for Apollo and Relievant, due to synergies expected to be gained from leveraging our existing